Another potential circulating NB biomarker is tyrosine hydroxylase mRNA, which is consistently increased in NB patients and used to evaluate Minimal Residual Disease causing relapse, even after additional consolidation therapy [42]. This evidence concerns the gene TH and neuroblastoma.